Wind data shows that as of August 30, more than 340 A-share pharmaceutical companies have released 2022 semi-annual reports, and more than half of the companies have achieved a year-on-year increase in net profit in the first half of the year.
Among them, 33 companies have a year-on-year increase in net profit attributable to the parent in the first half The speed exceeded 100%, and the year-on-year growth rate of net profit of the two companies, North China Pharmaceutical and Hualan Vaccine, exceeded 1000%
.
Overall, companies with outstanding performance are mainly concentrated in the medical device, CXO and traditional Chinese medicine sectors
.
Medical Devices (Image Source: Pharmaceutical Network)
The first half performance of the medical device sector is outstanding
The first half performance of the medical device sector is outstanding
According to the data, as of August 30, more than 70 A-share listed medical device companies have disclosed their performance reports for the first half of the year, of which over 60% of the companies' net profit attributable to the parent company in the first half of the year increased year-on-year
.
From the perspective of net profit scale, in the first half of the year, Mindray Medical had the highest net profit attributable to its parent, reaching 5.
288 billion yuan, followed by Daan Gene and Mingde Bio, with net profit attributable to its parent of 3.
56 billion yuan and 2.
76 billion yuan respectively
.
Judging from the year-on-year growth rate of net profit, the net profit attributable to the parent company of 6 medical device companies has increased by more than 100% year-on-year, including Yahuilong, Mingde Bio, Aotai Bio, Kaipu Bio, Daan Gene and Wanfu Bio, etc.
.
Among them, Yahuilong's net profit attributable to its mother increased by 651.
7% year-on-year, followed by Mingde Bio, with a growth rate approaching 300%
.
It is worth mentioning that many companies are still accelerating research and development behind the scenes while achieving outstanding results
.
Among them, Mindray Medical, as a leading enterprise in the medical device industry, invested as much as 1.
456 billion yuan in research and development in the first half of the year, a year-on-year increase of 25.
01%
.
Under the continuous research and development, the company's products continue to be enriched, and the technology continues to iterate, especially high-end products continue to achieve breakthroughs
.
In addition, in the first half of the year, Yahuilong’s R&D investment increased by 95%.
The company mainly increased its R&D efforts in microfluidics, sequencing, and biochemistry, and the R&D amount increased by 278% year-on-year
.
The industry believes that with the aging of the population and the promotion of chronic diseases, the enhancement of the general health awareness of the whole people, and the continuous improvement of residents' consumption structure, the market demand for medical devices will continue to grow
.
At the same time, with the development of new technologies for medical devices and the acceleration of import substitution, the scale of the industry is expected to expand
.
The data shows that the medical device market size in 2020 is about 811.
8 billion yuan
.
In the future, new medical infrastructure will become an important development line
In the future, new medical infrastructure will become an important development line
In recent years, the construction of new medical infrastructure projects has been in full swing, including a series of favorable policies to drive new medical infrastructure, the rapid growth of various domestic hospital construction projects, and the acceleration of domestic enterprises to make up for the shortcomings of high-end medical equipment
.
Looking forward to the future, new medical infrastructure will be the main theme of the medical and health service industry during the "14th Five-Year Plan" period.
The market space is broad, and therefore it has become one of the focuses of the capital market
.
Recently, Mindray Medical, which has received intensive attention from institutions, said in an investigation that it is expected that the hospital operation in the second half of the year will be significantly better than that in the first half of the year
.
In the next few years, new medical infrastructure will become an important development line for the domestic medical device market and Mindray Medical
.
It is understood that in this year's semi-annual report, Mindray Medical has disclosed that it is deeply involved in the new medical infrastructure in China, and it also closely follows the needs of overseas medical services to supplement shortcomings, and continues to break through the high-end customer base, achieving steady growth in performance
.
Libang Instruments mentioned in the question and answer session of institutional research that the investment in new national medical infrastructure is mainly divided into two parts: hard investment and soft investment
.
Among them, hard investment has clearly felt that the country has increased its efforts in recent years.
It believes that soft investment such as comprehensive medical informatization plans will be the key direction of the country's new medical infrastructure in the next few years.
For multi-hardware product lines, and In terms of technology, brand, channel and smart medical business, domestic medical device manufacturers with global competitiveness will be an opportunity for rapid growth
.
It is expected that the wave of new medical infrastructure will continue for at least 3-5 years
.
"The sea is wide and the fish leaps, and the sky is high for the birds to fly
.
" A number of brokerage research reports have analyzed that with the advancement of new medical infrastructure, domestic medical device products will accelerate iterative upgrades, have the hard power of innovative research and development, and head companies that deploy high-end hospitals overseas are expected to win more opportunities, which is worth looking forward to!
